Collegium Announces the Appointment of Shirley Kuhlmann as General Counsel
March 19 2018 - 8:00AM
Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the
appointment of Shirley Kuhlmann to the newly created position of
Executive Vice President and General Counsel and Secretary,
effective March 16, 2018. Ms. Kuhlmann will oversee all legal and
compliance matters for the company.
“We are pleased to have Shirley join our
leadership team at this exciting time,” said Mike Heffernan,
Collegium’s CEO. “Shirley’s previous role at Pepper Hamilton
combined with her in-depth knowledge and understanding of
Collegium, will bring immediate value as we execute our growth
strategy.”
Prior to joining Collegium, Ms. Kuhlmann was a
Partner in the Health Sciences Department of Pepper Hamilton LLP,
where she served as Collegium’s outside counsel. Ms. Kuhlmann has
over a decade of experience working with both private and public
companies on a range of commercial and transactional matters,
including financings, corporate governance and disclosure matters,
and mergers and acquisitions and other business combination
transactions. Ms. Kuhlmann holds a B.A. in Economics/Political
Science from Columbia University and a J.D. from Emory University
School of Law.
“I have been honored to represent Collegium as
outside counsel, and I am very excited to be joining the team at
this pivotal time in the Company’s development. I look forward to
working with this proven management team and executing on
Collegium’s mission to become the leader in responsible pain
management,” commented Ms. Kuhlmann.
About Collegium
Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company
focused on becoming the leader in responsible pain management by
developing and commercializing innovative, differentiated products
for patients suffering from pain.
About Xtampza ER
Xtampza® ER is Collegium’s first product
utilizing the DETERx technology platform. Xtampza ER is an
abuse-deterrent, extended-release, oral formulation of oxycodone
approved by the FDA for the management of pain severe enough to
require daily, around-the-clock, long-term opioid treatment and for
which alternative treatment options are inadequate.
Contact:Alex
Dasallaadasalla@collegiumpharma.com
Collegium Pharmaceutical (NASDAQ:COLL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Collegium Pharmaceutical (NASDAQ:COLL)
Historical Stock Chart
From Apr 2023 to Apr 2024